PT Bintang Toedjoe proudly extends its congratulations to the Indonesian Food and Drug Authority (BPOM RI) on its official recognition as a WHO Listed Authority (WLA) in medical product regulation, including pharmaceuticals, as announced by the World Health Organization (WHO). This recognition was granted jointly to BPOM RI and Australia’s Therapeutic Goods Administration (TGA), following an assessment confirming that both authorities meet WHO’s highest global standards for medical product regulatory systems.

As Indonesia’s national regulatory authority, BPOM RI has successfully undergone a rigorous technical evaluation based on WHO’s international benchmarks, demonstrating a regulatory system that is robust, transparent, science-based, and aligned with international best practices. WHO’s recognition further strengthens Indonesia’s position as a trusted medical product regulatory authority in the region, which is expected to bring significant positive impacts on the export potential of pharmaceutical products and health-related brands.

This achievement also recalls a key milestone in the continuous effort to enhance regulatory quality and local product standards, namely the WHO–BPOM visit to PT Bintang Toedjoe’s production facilities in October 2025. During the visit, WHO expressed its appreciation for Bintang Toedjoe’s strong commitment to implementing modern manufacturing standards and fostering research-based collaboration in the development of herbal products. The visit reflected a strategic partnership and synergy between WHO, BPOM, and the industry in advancing the quality and global competitiveness of Indonesian products.

The attainment of WHO Listed Authority (WLA) status stands as tangible evidence of Indonesia’s long-term commitment to strengthening its regulatory system and becoming an integral part of the internationally recognized regulatory community. It is hoped that this milestone will serve as a strong catalyst for national industries to continue innovating, improving quality, and expanding access to global markets in pursuit of better health outcomes for communities worldwide.